- Imatinib Plasma Monitoring-Guided Dose Modification for Managing Imatinib-Related Toxicities in Gastrointestinal Stromal Tumor Patients
-
Yoon S, Ryu MH, Yoo C, Beck MY, Ryoo BY, Kang YK
- KMID: 1793034
- J Korean Med Sci.
- 2013 Aug;28(8):1248-1252.
- doi: 10.3346/jkms.2013.28.8.1248
Imatinib, the first-line treatment in patients with advanced gastrointestinal stromal tumors (GIST), is generally well tolerated, although some patients have difficulty tolerating the standard dose of 400 mg/day. Adjusting imatinib... -
- CITED
-
- Close
- SHARE
-
- Close
- Concurrent Male Gynecomastia and Testicular Hydrocele after Imatinib Mesylate Treatment of a Gastrointestinal Stromal Tumor
-
Kim H, Chang HM, Ryu MH, Kim TW, Sohn HJ, Kim SE, Kang HJ, Park S, Lee JS, Kang YK
- KMID: 1778518
- J Korean Med Sci.
- 2005 Jun;20(3):512-515.
- doi: 10.3346/jkms.2005.20.3.512
We report a gastrointestinal stromal tumor (GIST) patient with male gynecomastia and testicular hydrocele after treatment with imatinib mesylate. A 42 yr-old male patient presented for management of hepatic masses.... -
- CITED
-
- Close
- SHARE
-
- Close
- Long-Surviving Patients with Recurrent GIST after Receiving Cytoreductive Surgery with Imatinib Therapy
-
Choi WH, Kim S, Hyung WJ, Yu JS, Park CI, Choi SH, Noh SH
- KMID: 1758574
- Yonsei Med J.
- 2009 Jun;50(3):437-440.
- doi: 10.3349/ymj.2009.50.3.437
In the treatment of recurrent or metastatic gastrointestinal stromal tumors (GIST), good prognoses may not be expected by surgery alone. Recently, imatinib has been applied for the treatment of GISTs,... -
- CITED
-
- Close
- SHARE
-
- Close
- Imatinib mesylate-induced interstitial lung disease in a patient with prior history of Mycobacterium tuberculosis infection
-
Lee NR, Jang JW, Kim HS, Yhim HY
- KMID: 2366019
- Korean J Intern Med.
- 2015 Jul;30(4):550-553.
- doi: 10.3904/kjim.2015.30.4.550
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
